Title: Effects of genetic polymorphisms of XRCC1 on the efficacy of platinum-based chemotherapy for advanced nonsmall cell lung cancer
Abstract: Objective To investigate the relationship between genetic polymorphisms of XRCC1 and survival of patients with advanced non-small cell lung cancer( NSCLC) treated with platinum-based chemotherapy. Methods A total of 204 patients with advanced NSCLC were routinely treated by platinum-based chemotherapy. The genotypes were analyzed by MALDITOF-MS method using DNA samples isolated from peripheral blood before treatment. Besides,5% of the samples were extracted randomly for sequencing to test the accuracy of this method. The association between SNPs of XRCC1( 399) and prognosis to platinum-based chemotherapy in the patients with advanced NSCLC was analyzed. Results Of 204 patients,61 achieved partial response,116 achieving stable response,and 27 having progressive disease. The overall effective rate was 29. 9%( 61 /204), and the ineffective rate was 70. 1%( 143 /204). The effective rates of patients with XRCC1( 399) G/ G genotype and G/ A + A/ A genotype were 36. 9%( 38 /103) and 22. 8%( 23 /101),respectively( P 0. 05). The sensitivity to DDP of XRCC1( 399) G/ G allele carriers was 1. 983-fold of that of G/ A + A/ A allele carriers( 95% confidence interval CI: 1. 073 ~ 3. 662,P = 0. 028). Median survival time,1-year survival and 2-year survival rates of patients with XRCC1( 399) G/ G genotype and G/ A + T / T genotype were 12. 0 months,52. 4% and 11. 7% and 10. 0 months,37. 6% and 3.0%,respectively( P 0. 05). Conclusions Polymorphisms of XRCC1 might be associated with overall survival period in patients with advanced NSCLC after treatment with platinumbased chemotherapy,which might be the predictive markers for overall survival.
Publication Year: 2013
Publication Date: 2013-01-01
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot